Trials / Unknown
UnknownNCT02172937
Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study
Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Karolinska Institutet · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and efficacy using decidual stromal cell therapy for graft versus host disease after allogeneic hematopoietic stem cell transplantation. The hypothesis to be tested is that the cells are safe to infuse and that they have a positive clinical effect.
Detailed description
Patients with GVHD grade 2-4, will receive decidual stromal cells at approximately 1-2x10\^6 cells/kg at one or more occasions dependent on clinical response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Decidual Stromal Cells thawed in plasma | |
| BIOLOGICAL | Decidual Stromal Cells thawed in human albumin |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-06-24
- Last updated
- 2014-11-11
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02172937. Inclusion in this directory is not an endorsement.